Lifecore Biomedical, Inc. (NASDAQ:LFCR) CEO Paul Josephs Acquires 17,000 Shares of Stock

Lifecore Biomedical, Inc. (NASDAQ:LFCR) CEO Paul Josephs acquired 17,000 shares of Lifecore Biomedical stock in a transaction dated Wednesday, January 8th. The shares were bought at an average price of $5.74 per share, for a total transaction of $97,580.00. Following the transaction, the chief executive officer now owns 559,717 shares of the company’s stock, valued at approximately $3,212,775.58. The trade was a 3.13 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Lifecore Biomedical Price Performance

Lifecore Biomedical stock opened at $5.80 on Thursday. Lifecore Biomedical, Inc. has a 52-week low of $3.68 and a 52-week high of $8.90. The company has a quick ratio of 0.80, a current ratio of 1.83 and a debt-to-equity ratio of 12.90. The firm’s fifty day moving average is $7.05 and its 200 day moving average is $5.82. The company has a market cap of $213.60 million, a price-to-earnings ratio of 72.50 and a beta of 0.98.

Lifecore Biomedical (NASDAQ:LFCR) last announced its earnings results on Thursday, January 2nd. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.02. Lifecore Biomedical had a net margin of 5.09% and a negative return on equity of 382.65%. Sell-side analysts forecast that Lifecore Biomedical, Inc. will post -0.99 EPS for the current fiscal year.

Institutional Investors Weigh In On Lifecore Biomedical

Institutional investors have recently modified their holdings of the stock. Legion Partners Asset Management LLC increased its position in shares of Lifecore Biomedical by 0.6% during the 2nd quarter. Legion Partners Asset Management LLC now owns 2,968,409 shares of the company’s stock valued at $15,228,000 after purchasing an additional 18,182 shares during the last quarter. Geode Capital Management LLC increased its position in Lifecore Biomedical by 10.3% during the third quarter. Geode Capital Management LLC now owns 597,685 shares of the company’s stock valued at $2,948,000 after acquiring an additional 55,703 shares during the last quarter. State Street Corp increased its position in Lifecore Biomedical by 10.2% during the third quarter. State Street Corp now owns 334,360 shares of the company’s stock valued at $1,648,000 after acquiring an additional 30,916 shares during the last quarter. Marshall Wace LLP raised its stake in shares of Lifecore Biomedical by 87.3% in the second quarter. Marshall Wace LLP now owns 300,120 shares of the company’s stock valued at $1,540,000 after acquiring an additional 139,887 shares during the period. Finally, DCF Advisers LLC lifted its holdings in shares of Lifecore Biomedical by 2.1% in the 2nd quarter. DCF Advisers LLC now owns 290,684 shares of the company’s stock worth $1,491,000 after acquiring an additional 6,000 shares during the last quarter. 83.36% of the stock is owned by institutional investors.

Analyst Ratings Changes

LFCR has been the subject of several research analyst reports. Craig Hallum raised their target price on shares of Lifecore Biomedical from $8.00 to $10.00 and gave the company a “buy” rating in a research note on Friday, November 22nd. Stephens reaffirmed an “equal weight” rating and issued a $6.00 target price on shares of Lifecore Biomedical in a report on Friday, January 3rd.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.